ARTICLE

Novel deletions affecting the *MEG3*-DMR provide further evidence for a hierarchical regulation of imprinting in 14q32

Jasmin Beygo¹, Miriam Elbracht², Karel de Groot³, Matthias Begemann², Deniz Kanber¹, Konrad Platzer⁴, Gabriele Gillissen-Kaesbach⁴, Anne Vierzig⁵, Andrew Green^{6,7}, Raoul Heller⁸, Karin Buiting^{*,1} and Thomas Eggermann^{*,2}

The imprinted region on chromosome 14q32 harbors several maternally or paternally expressed genes as well as two DMRs (differentially methylated regions), the IG-DMR and the *MEG3*-DMR, which both act as imprinting control centers. Genetic aberrations affecting the imprinted gene cluster in 14q32 result in distinct phenotypes, known as maternal or paternal uniparental disomy 14 phenotypes (upd(14)mat, upd(14)pat). In both syndromes, three types of molecular alterations have been reported: uniparental disomy 14, deletions and epimutations. In contrast to uniparental disomy and epimutations, deletions affecting regulatory elements in 14q32 are associated with a high-recurrence risk. Based on two single deletion cases a functional hierarchy of the IG-DMR as a regulator for the methylation of the *MEG3*-DMR has been proposed. We have identified two novel deletions of maternal origin spanning the *MEG3*-DMR, but not the IG-DMR in patients with upd(14)pat syndrome, one *de novo* deletion of 165 kb and another deletion of 5.8 kb in two siblings. The 5.8 kb deletion was inherited from the phenotypically normal mother, who carries the deletion in a mosaic state on her paternal chromosome 14. The methylation at both DMRs was investigated by quantitative next generation bisulfite sequencing and revealed normal methylation patterns at the IG-DMR in all patients with the exception of certain CpG dinucleotides. Thus, we could confirm that deletions of the *MEG3*-DMR does not generally influence the methylation pattern of the IG-DMR, which strengthens the hypothesis of a hierarchical structure and distinct functional properties of the two DMRs.

European Journal of Human Genetics (2015) **23**, 180–188; doi:10.1038/ejhg.2014.72; published online 7 May 2014

INTRODUCTION

The human chromosomal region 14q32 carries a cluster of imprinted genes, which includes the paternally expressed genes *delta-like 1* homolog, *Drosophila* (*DLK1*) and *RTL1* (Retroposon-like 1, *PEG11*) as well as the maternally expressed genes *MEG3* (alias *GTL2*), *RTL1as*, *MEG8*, numerous C/D box small nucleolar (sno)RNAs and microRNAs.^{1–4} In addition, the 14q32-imprinted region harbors two differentially methylated regions (DMRs), the germline-derived primary intergenic DMR between *DLK1* and *MEG3* (IG-DMR) and the postfertilization-derived secondary *MEG3*-DMR, which are methylated on the paternal and unmethylated on the maternal chromosome 14 in most cells (see Figure 1).^{5–8} Genetic and epigenetic alterations affecting the imprinted gene cluster in 14q32 result in two different phenotypes currently known as maternal or paternal uniparental disomy 14 phenotypes (upd(14)mat, upd(14)pat). The upd(14)pat syndrome is characterized by polyhydramnios, a small bell-shaped thorax, facial dysmorphisms, abdominal wall defects, distal arthrogryposis and mental retardation,^{9,10} whereas the upd(14)mat syndrome is characterized by pre and postnatal growth retardation, neonatal hypotonia, feeding

problems and precocious puberty.^{11–13} In both syndromes, three types of molecular alterations have been reported: uniparental disomy, deletions and epimutations.^{7,14–19} In contrast to uniparental disomy and epimutations, deletions affecting regulatory elements in 14q32 on the maternal or the paternal allele are associated with a high-recurrence risk.^{7,19} It has been shown that both the *MEG3*- and the IG-DMR function as imprinting control centers in the placenta and the body. A functional hierarchy of the IG-DMR as a regulator for the methylation pattern of the *MEG3*-DMR has been postulated based on a patient with a maternally inherited deletion of 8.6 kb affecting the IG-DMR but not the *MEG3* promoter,¹⁹ which was associated with an epimutation (hypermethylation) of the *MEG3*-DMR and a phenotype in body and placenta. In contrast, in another patient in the same study with a deletion of 4.3 kb on the maternal allele affecting the *MEG3*-DMR but not the IG-DMR, this deletion was associated with normal methylation at the IG-DMR (Figure 1). In this patient the placenta showed normal appearance. In both patients the deletion results in a typical upd(14)pat syndrome.

Here we report on the identification and molecular characterization of two additional cases with deletions on chromosome 14q32

¹Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany; ²Institute of Human Genetics, RWTH Aachen, Aachen, Germany; ³MRC Holland, Amsterdam, The Netherlands; ⁴Institut für Humangenetik, Universität zu Lübeck, Lübeck, Germany; ⁵Department of Neonatology and Pediatric Intensive Care, Children's Hospital, University of Cologne, Cologne, Germany; ⁶National Centre for Medical Genetics, Our Lady's Hospital, Crumlin, Dublin, Ireland; ⁷School of Medicine and Medical Science University College, Dublin, Ireland; ⁸Institute of Human Genetics, University of Cologne, Cologne, Germany

*Correspondence: Dr K Buiting, Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany, Hufelandstrasse 55, 45122 Essen, Germany. Tel: +49 201 7234555; Fax: +49 201 7235900; E-mail: Karin.buiting@uni-due.de or Professor Dr T Eggermann, Institute of Human Genetics, RWTH Aachen, Aachen, Germany, Pauwelsstrasse 30, 52074 Aachen, Germany. Tel: +49 241 8088008; Fax: +49 241 8082394; E-mail: teggermann@ukaachen.de

Received 6 December 2013; revised 18 February 2014; accepted 25 February 2014; published online 7 May 2014

Figure 1 Schematic overview of the imprinted region on chromosome 14q32. The scheme depicts the deletions described here (patients 1, 2 and 3) and in a previous report by Kagami *et al.*¹⁹ in relation to the imprinted genes in the region 14q32. The MS-MLPA probes of the region are indicated by black and gray lines. Black lines represent MLPA probes for dosage; gray lines represent MLPA probes for dosage and methylation. Blue, paternally expressed genes; red, maternally expressed genes; gray, DMRs (differentially methylated regions). Not drawn to scale.

affecting the *MEG3*-DMR but not the IG-DMR: one single patient with a maternal *de novo* microdeletion and two siblings with a microdeletion inherited from their mother who carries this deletion in a mosaic state on her paternal chromosome 14. To examine the aforementioned hypothesis of a hierarchical interaction and the distinct functional properties of the two DMRs more precisely we performed quantitative methylation analyses in our patients and the patient with the isolated 4.3 kb *MEG3*-DMR deletion published by Kagami *et al.*¹⁹ by next generation bisulfite sequencing of both DMRs.

MATERIALS AND METHODS

Subjects and samples

Three individuals with clinical features suggestive for upd(14)pat syndrome were referred to the departments of Human Genetics in Lübeck (patient 1) and Aachen (patients 2 and 3). The families agreed to participate in the molecular studies. The studies were approved by the ethics committees of the participating institutions. A DNA sample from the patient with the 4.3 kb *MEG3* deletion published before¹⁹ was kindly provided by Andrew Green.

DNA extraction

DNA was extracted from peripheral lymphocytes using the Flexigene Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocols, or by a simple salting-out procedure.

Methylation-specific PCR (MS-PCR)

Genomic DNA was purified from whole blood and treated with sodium bisulfite according to standard methods. MS-PCR analysis of the *MEG3*-DMR was carried out as described by Dietz *et al.*²⁰ Touchdown PCR was used as follows: annealing temperatures were 5 cycles at 70 °C for 30 s, 5 cycles at 65 °C for 30 s and 30 cycles for 60 °C.

Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)

Gene dosage of the imprinted *DLK1/MEG3* locus and methylation of the *MEG3* promoter region on chromosome 14q32 were analyzed by MS-MLPA using the SALSA MLPA KIT ME032-X1 kit (MRC Holland, Amsterdam, Netherlands). This newly established MS-MLPA kit contains 21 probes for gene dosage analysis of the chromosomal region 14q32 and three methylation sensitive probes for the *MEG3* promoter region. Hybridization, ligation and PCR reactions were carried out according to the manufacturer's instructions. Amplification products were analyzed by capillary electrophoresis using the ABI3100 capillary sequencer. Data analysis was carried out using the Gene Marker Software (Softgenetics, State College, PA, USA).

Microarray analysis

For genome-wide copy number analysis the Affymetrix human SNP array 6.0 (Affymetrix, Santa Clara, CA, USA) was carried out following the

manufacturer's protocol. Data analysis was performed with the Genotyping Console and Chas software (Affymetrix).

Long-range PCR

To determine the exact size of the deletions and to identify the breakpoints on the DNA sequence level a long-range PCR was carried out using the Expand long-range dNTPack (Roche, Mannheim, Germany). Primers were generated spanning the sites of MLPA probes which showed a normal dosage in the siblings (patients 2 and 3) or spanning SNP or copy number probes of the array in patient 1 (for primer sequences see Supplementary Table 1). PCR was performed according to the manufacturer's manual with a magnesium-chloride (MgCl₂) containing buffer, a final primer concentration of 0.6 μM, with or without 6% DMSO and a DNA input of about 200 ng. The PCR program was carried out as described in the manual with an elongation time of 9 min and 28 cycles or 8 min and 20 cycles respectively in the third stage. The PCR-product derived from the allele harboring the deletion was either gel purified using the QiaQuick gel extraction Kit (Qiagen) or by ExoSAP-It (USB, Santa Clara, CA, USA) as described in the manufacturers' protocols. Sequencing was carried out with the BigDye Terminator v1.1 Cycle Sequencing Kit on an ABI3100 automatic capillary genetic analyzer (Applied Biosystems, Darmstadt, Germany). Sequence analysis was performed with Sequencing Analysis (Applied Biosystems) and Geneious (Biomatters, Auckland, New Zealand).

Quantitative PCR (qPCR)

A real-time PCR assay for the promoter region of *MEG3* was performed as previously described by Buiting *et al.*¹⁶

Multilocus methylation-specific single nucleotide primer extension (MS-SNuPE)

To confirm the altered methylation pattern at the *MEG3* locus, MS-SNuPE was performed as previously described by Begemann *et al.*²¹

DNA methylation analysis of the *MEG3*-DMR and IG-DMR by next generation bisulfite sequencing

Bisulfite treatment was performed using the EZ DNA Methylation-Gold Kit (Zymo Research Europe, Freiburg, Germany) according to the manufacturer's instructions. For each individual, bisulfite amplicon libraries were generated and sample-specific barcode sequences were added. The amplicons were purified, diluted and clonally amplified in an emulsion PCR before sequencing on the Roche/454 GS junior system (Branford, CT, USA). A detailed description has been published previously.²² Primer sequences are listed in Supplementary Table 1. For subsequent data analysis the Amplifyer software was used (<https://bitbucket.org/svenrahmann/amplifyer/downloads>). A minimum of 1200 reads for each sample was obtained. Only reads with a conversion rate over 95% were considered.

RESULTS

Clinical findings

Patient 1. The patient was born to healthy non-consanguineous parents after 32+2 weeks of gestation. The pregnancy was complicated by polyhydramnion but placentomegaly was not reported. Measurements at birth were 2.6 kg (+1.6 SD), 47 cm (+1.4 SD) and head circumference 32 cm (+1.2 SD). The patient showed a hypoplastic thorax with 'coat hanger'-like ribs, retromicrognathia and muscular hypotonia. He had feeding difficulties and needed assisted ventilation until the age of 3 months. At this time a tracheostoma was implanted which remained until the age of 11 months. Feeding difficulties with recurrent aspirations necessitated percutaneous endoscopic gastrostomy feeding until the age of 17 months when he got a MicKey Button. At the age of 3 y and 4 months oral feeding was still very difficult. He could walk without support. He spoke few words, comprehension was very limited. His height was 93 cm (−2 SD), weight 14.2 kg (mean), OFC 50.5 cm (mean), respectively. He still shows muscular hypotonia.

At the age of 15 months his height was 76 cm (−1.2 SD), weight 10.5 kg (Mean) and head circumference 49.3 cm (+0.4 SD), respectively. He still showed muscular hypotonia and generalized developmental delay. At the age of 27 months he was able to walk a few steps with support. He only spoke a few words. Comprehension was not age-appropriate.

Patients 2 and 3. The two children were born as the second and third child of consanguineous healthy Turkish parents (Figure 2a). The father's height is 176 cm, the mother's height is 167 cm. Both parents successfully finished secondary education. The first pregnancy of the family ended with a preterm birth at 18 weeks, further information was not available. Apart from that, the family history was unremarkable. The oldest son (II-2) is healthy.

Both younger children (patients 2 and 3, II-3 and II-4 in the pedigree) were delivered at 35 weeks of gestation because of polyhydramnion and preterm labor. Information about the placenta was not available.

Detailed clinical data of the siblings are listed in Table 1. The boy (II-3, patient 2) was delivered by Cesarean section because of pathological CTG records and asphyxia. Birth measurements were within the normal range (3125 g (1.5 SD), 46 cm (mean), 35 cm head circumference (2.1 SD)). The 1–5 and 10 min Apgar-scores were 1/4/4, marked muscular hypotonia was detected. Intubation and assisted ventilation were carried out for 16 days. Temporary occurring neonatal seizures were treated by Phenobarbital. His ventilation stabilized but he required oxygen administration until the age of 4 y. Laryngopharyngeal dysfunction with recurrent aspirations necessitated percutaneous endoscopic gastrostomy feeding for the first few years.

The girl (II-4, patient 3) was delivered vaginally with normal birth measurements (2800 g (1.1 SD), 45 cm (−0.1 SD), 32.5 cm head circumference (+0.7 SD)). By 1–5 y and 10 min Apgar-scores of 5/2/5 and muscular hypotonia, she needed assisted ventilation by CPAP for the first 42 h but then no further ventilator support. She started sucking briefly after birth. In general the clinical course was milder in the girl than in her older brother.

Both children had the typical bell-shaped thorax with the 'coat hanger' appearance of the ribs on x-rays (Figure 2b) and the dysmorphic facial features such as short-palpebral fissures, anteverted nares, broad-nasal bridge, protruding philtrum and retromicrognathia. They showed frontal bossing with temple narrowing and full

cheeks. The ears were deep set, the neck short and webbed (Figure 2c).

Both children, the boy more than the girl, had bilateral talipes calcaneovalgus and limited joint mobility especially in the wrist and fingers. Bilateral inguinal hernia repair was carried out in the boy at the age of 2 months, whereas his sister showed rectus diastasis and a small umbilical hernia.

The clinical findings of the boy improved over time. At the age of 5, 6 or 12 y (Figure 2c), he was able to walk without help and communicated in two word sentences. He needed no further medical support for ventilation or feeding. Formal intelligence testing had not been performed.

Molecular genetic findings

Methylation analysis in patient 1 performed by MS-PCR for the *MEG3* promoter region revealed the presence of the methylated paternal allele only, indicating that the patient has upd(14)pat, an imprinting defect or a deletion affecting the *MEG3* locus. Microsatellite analysis did not provide any evidence for uniparental disomy. Approximately 165 kb deletion on chromosome 14q32 was detected by Affymetrix genome-wide human SNP array 6.0 analysis (Santa Clara, CA, USA). The deletion includes *MEG3*, *RTL1*, *MEG8* and most of the miRNA genes, but not the IG-DMR. MS-MLPA was used to confirm the deletion and to determine that the deletion affects the maternal allele (Figure 3a). MS-MLPA analysis in the mother's DNA showed a normal result, indicating that the deletion in the patient occurred *de novo* (data not shown). Long-range PCR was used to amplify the deletion junction fragment and to further characterize the deletion size and breakpoints on the DNA sequence level (165.153 kb, hg19: chr14:g.101285913_101451066del see Figures 1 and 3b). Sequence comparison with a reference sequence (hg19) revealed a 6 bp insertion (TTCCCC) between the proximal and distal breakpoints (Figure 3b).

Initial genetic testing in patient 2 was performed by MS-PCR at the *MEG3*-DMR. Only the methylated paternal allele was present, microsatellite analysis showed biparental inheritance of chromosomes 14. A qPCR at the promoter region of *MEG3* and a routine diagnostic genome-wide human SNP array analysis (resolution 100 kb) revealed no evidence for a deletion. MS-MLPA analysis for the 14q32 region was not available at that time. Thus it was concluded that the patient has a upd(14)pat syndrome probably owing to a primary epimutation. Five years later a sister (patient 3) was born with similar clinical features of a upd(14)pat syndrome. The clinical diagnosis could be confirmed by methylation analysis using a MS-SNuPE assay for the *MEG3*-DMR. A small deletion which was not detected before by genome-wide array analysis and qPCR could now be detected by MS-MLPA (Figure 3a) in both siblings: a 50% reduced dosage for three MLPA probes in the *MEG3* promoter region was observed in the girl and her brother. A retrospective data analysis of the SNP array performed in patient 2 revealed that the deleted region has a low coverage of probes (2 probes) and therefore the deletion was not detectable by standard bioinformatic parameters. The same deletion was found in lymphocytes of the phenotypically unremarkable mother in a mosaic state with a signal reduction of ~30% for the three probes. Long-range PCR was used to identify and further characterize the deletion breakpoints on the DNA sequence level. The deletion was found to be 5.8 kb in size encompassing the *MEG3*-DMR and the first three exons of the *MEG3* gene (exon numbering based on NR_002766.2; hg19: chr14:g.101291322_101297145del; the patient has been submitted to LOVD (ID 00011680; <http://databases.lovd.nl/>) see Figures 1 and 3c).

Figure 2 (a) Pedigree of patients 2 (II.3) and 3 (II.4) with upd(14)pat-syndrome phenotype. (b) X-rays of patients 2 and 3 showing the small, bell-shaped thorax with the characteristic 'coat hanger'-like appearance of the ribs. (c) Patients 2 and 3. Patient 2 is shown at the age of 5, 6 or 12 y and his less severe affected sister at 4 and 10 months.

Both, the 165 kb and the 5.8 kb deletion affect the *MEG3*-DMR but not the IG-DMR. Kagami *et al*¹⁹ reported a similar deletion of 4.3 kb including the *MEG3*-DMR, exon 1, exon 2 and part of exon 3, which does not affect methylation at the IG-DMR (Figure 3). In contrast, an 8.6 kb deletion including the IG-DMR but not the *MEG3*-DMR reported by the same group in another patient was associated with hypermethylation of the *MEG3*-DMR in blood DNA.

Since all applied tests investigated the methylation status of the *MEG3*-DMR but not the IG-DMR, we applied deep bisulfite sequencing of the *MEG3*-DMR and the IG-DMR using the Roche 454/GS junior system in our three patients to obtain high resolution

quantitative DNA methylation patterns for the both regions. We also included the patient with the similar *MEG3* deletion described by Kagami *et al*¹⁹ (patient with the 4.3 kb deletion), the parents of our cases 2 and 3, four normal controls, a patient with upd(14)pat and a patient with upd(14)mat in the analysis. Analysis of the sequence reads was performed using the open source amplifyer software. As expected for the *MEG3*-DMR, all patients with a *MEG3* deletion and the patient with upd(14)pat showed relative hypermethylation of 92 to 98% owing to the absence of the unmethylated maternal allele and the patient with upd(14)mat showed relative hypomethylation of 8.2% owing to the absence of the methylated paternal allele

Table 1 Clinical findings

	Patient 1	Patient 2	Patient 3
Gestational age at birth (weeks)	32 + 2	35	35
Birth weight	2600 g (+ 1.6 SD)	3125 g (+ 1.5 SD)	2800 g (+ 1.0 SD)
Birth height	47 cm (+ 1.4 SD)	46 cm (mean)	45 cm (−0.1 SD)
Head circumference	32 cm (1.2 SD)	35 cm (2.1 SD)	32.5 cm (0.7 SD)
Delivery	Vaginally	Cesarean	Vaginally
Polyhydramnios	+	+	+
Placentomegaly	−	NA	NA
<i>Facial features</i>			
Frontal bossing	NR	+	+
Temple narrowing	NR	+	+
Full cheeks	NR	+	+
Short-palpebral fissures	NR	+	+
Broad-nasal bridge	NR	+	+
Protruding philtrum	NR	+	+
Short/webbed neck	NR	+	+
Muscular hypotonia	+	+	+
'Coat hanger'-like ribs	+	+	+
Assisted ventilation	+ (3 months)	+ (16 days) oxygen administration for 4 y	+ (42 h)
Feeding difficulties	+	+	−
<i>Congenital anomalies</i>			
Inguinal hernia	NR	+	−
Rectus diastasis	NR	−	+
Umbilical hernia	NR	−	+
Deletion	165 kb	5.8 kb	5.8 kb
Mode of inheritance	<i>de novo</i>	Maternal	Maternal
<i>Methylation</i>			
<i>MEG3</i> -DMR	Hyper	Hyper	Hyper
IG-DMR	Normal	Normal	Normal

Abbreviations: DMR, differentially methylated region; NA, data not available; NR, not reported.

(Figure 4a). The mother of patients 2 and 3, who has the deletion in a mosaic state, was found to have an average methylation level of 36.8%. Since a normally methylated cell with two intact alleles for an imprinted gene has a methylated and an unmethylated allele and therefore a methylation level of ~50%, the mother has ~74% normally methylated cells and 26% cells carrying the deletion on the methylated paternal *MEG3* copy. This is in agreement with the MS-MLPA results obtained in the gene dosage analysis.

For the IG-DMR we investigated 15 of 19 CpG dinucleotides of the CG6 region, which has been analyzed by Kagami *et al.*¹⁹ via bisulfite cloning and sequencing. Between 1200 and 3200 sequence reads each for the 12 analyzed individual samples were obtained. Interestingly, in the normal controls only three of the 15 CpGs (CpG6-8, see Figure 4b) investigated showed a methylation level of about 50% which is the expected value for an allele-specifically methylated region at an imprinted locus. All other 12 CpGs studied showed an increased methylation level with an average methylation between 61 and 74%. Furthermore, the upd(14)mat sample showed 6–13% methylation for CpG6-8 and an overall methylation average of 32%, indicating that the maternal allele is not completely unmethylated. This is in agreement with the methylation pattern obtained by bisulfite Sanger sequencing in an upd(14)mat DNA sample shown by Kagami *et al.*¹⁹

For most of the CpGs studied, the deletion patients did not differ from the normal controls. But interestingly, all four patients including the patient with the 4.3 kb deletion published by Kagami *et al.*¹⁹ showed a nearly identical pattern of hypermethylation at certain CpGs, especially at CpG 3, 11 and 14, compared with all normal controls (Figure 4b). The mother of our cases 2 and 3, however, showed a normal methylation pattern at all CpGs.

DISCUSSION

Based on the findings in two single patients with small deletions of maternal origin affecting only one of the imprinting regulatory elements in 14q32, the IG-DMR or the *MEG3*-DMR, it has been proposed that the IG-DMR acts as an upstream regulator for the methylation pattern of the *MEG3*-DMR. According to this hypothesis, a maternal deletion of the IG-DMR alone leads to a hypermethylation of the *MEG3*-DMR, whereas a maternal deletion of the *MEG3*-DMR alone does not change the methylation of the IG-DMR.¹⁹

We have now identified two additional patients with a deletion of the *MEG3*-DMR alone, one single patient with a maternal *de novo* microdeletion and two siblings with a microdeletion inherited from their mother who is a somatic mosaic for this deletion. By deep bisulfite sequencing we could confirm that, in general, these *MEG3* deletions do not influence the methylation pattern of the IG-DMR,

Figure 3 Results of the (a) MS-MLPA analysis and (b, c) the Sanger sequencing of the junction fragments obtained by long-range PCR for breakpoint identification. (a) The MS-MLPA for patient 1 showed a reduced dosage of about 50% for the nine probes encompassing *MEG3*, *RTL1* and part of the miRNA cluster confirming the presence of a heterozygous deletion (plot and table). The probes for *DLK1* and (the two probes) next to the *IG-DMR* displayed a normal dosage (around 1.0). A strong hypermethylation was demonstrated by the methylation-specific probes for the *MEG3*-DMR indicating that the deletion occurred on the unmethylated maternal allele (lower part of the table; normal methylation value should be ~0.5). Results for the patients' mother were normal (not shown), so that the deletion seemed to have occurred *de novo*. For patients 2 and 3 the dosage of three MLPA probes for the 5' end of *MEG3* are reduced by ~50% indicating the presence of a heterozygous deletion (plot and table). Dosage reduction in the mother was ~30%, pointing to a mosaic state of the deletion. Results of the methylation-specific probes showed a strong hypermethylation in the two patients and a slight hypomethylation of about 36% in the mother, who therefore carries the deletion on the paternal allele (Data for patient 3 not shown). (b) and (c) Sanger sequencing results for the deletion breakpoints. For patient 1 a 165 kb deletion comprising a 6 bp insertion between the proximal and distal breakpoints was observed (chr14:g.101285913_101451066del, hg19). For patients 2 and 3 as well as their mother a 5.8 kb deletion was present. The breakpoint junctions are uncertain at the triple C position (underlined; chr14:g.101291322_101297145del, hg19).

Figure 4 Comparative methylation heatmaps for (a) the *MEG3*-DMR and (b) the IG-DMR. Each square represents a CpG dinucleotide with its average methylation level, each line a specific sample. The average methylation over the analyzed region is given in percentage under the sample ID together with the number of analyzed reads in brackets. The methylation was analyzed over 11 CpGs at the *MEG3*-DMR and over 15 CpGs at the IG-DMR. P indicates patient; * indicates patient with the 4.3 kb deletion described by Kagami *et al.*¹⁹

which strengthens the hypothesis of a hierarchical structure and distinct functional properties of the two DMRs.¹⁹ However, nearly identical changes in methylation levels were found at certain CpGs at the IG-DMR in our three patients plus the patient with the 4.3 kb deletion described by Kagami *et al.*¹⁹ but not in any of the normal

controls, suggesting that the *MEG3* deletion on the maternal chromosome slightly influences the methylation at the IG-DMR. Interestingly we found that only three of the CpGs studied (CpGs 6–8), showed a methylation level of about 50% as expected for an allele-specifically methylated region at an imprinted locus. All other

CpGs showed methylation >50%. The most likely explanation for this observation is that the maternal allele is not unmethylated in all cells. This is supported by the results obtained by deep bisulfite sequencing for the upd(14)mat sample which showed an average methylation level of 32% and also by the methylation pattern reported by Kagami *et al*¹⁹ in a upd(14)mat sample using bisulfite Sanger sequencing.

In the mother of cases 2 and 3 the deletion affects the paternally methylated *MEG3*-DMR and the silenced *MEG3* gene copy, but not the methylation pattern at the IG-DMR. In contrast to the mother of the patient described by Kagami *et al*¹⁹ (patient with the 8.6 kb deletion), who has a deletion affecting the IG-DMR on the paternal chromosome and who has clinical features of upd(14)mat syndrome, the mother of our cases 2 and 3 has no phenotypic features of upd(14)mat. This suggests that the *MEG3*-DMR on the paternal copy does not contain a *cis*-acting regulatory element for *DLK1* expression at least within the deleted region as assumed for the IG-DMR¹⁹ or that the degree of cells carrying the deletion owing to the mosaic situation in the mother is too low to lead to a phenotypic effect. There is no comparable mouse model with a similar deletion. Only one mouse model with a targeted deletion upstream of the *Meg3* gene has been reported so far.²³ It could be shown that after paternal but also after maternal transmission mice carrying this deletion are indistinguishable from wild-type animals. They showed no phenotype and no change in the expression and imprinting of *Dlk1* or *Meg3*. However, this deletion spans a 2.8 kb upstream region and leaves the *Meg3* gene, *Meg3* promoter and all but 100 bp of the *Meg3*-DMR intact and therefore it is not comparable with the deletion in our family.

Molecular genetics and clinical evaluations of patients and families revealed that almost all of the deletions affecting the IG-DMR and/or *MEG3*-DMR are associated with a high-recurrence risk for a upd(14)pat or a upd(14)mat syndrome, depending on the parental origin of the deletion (for review see Ogata *et al*⁸). Based on the absence of any phenotypic feature of upd(14)mat in the mother of our cases 2 and 3, it seems that a deletion restricted to the *MEG3*-DMR and affecting the paternal allele can be compatible with a normal phenotype. However, further patients are needed to elucidate the pathogenicity of such a deletion after paternal transmission as this is only a single case and since the mother is a somatic mosaic for the deletion.

As the family of cases 2 and 3 illustrates, it is important to have a reliable molecular genetic testing system to identify especially small deletions because of the high-recurrence risk. After the birth of the first child in our family (patient 2) we could not find evidence for a deletion (i) the sequence studied by qPCR maps 0.6 kb centromeric to the proximal deletion breakpoint and therefore failed to detect the deletion; (ii) owing to the small size of the deletion, the low coverage of probes in the deletion region (two SNPs) and the application of standard bioinformatic parameters used, the deletion escaped the detection by Genome-Wide Human SNP 6.0-Array analysis. No other testing system for this region was available at that time. Only after the development of a MS-MLPA containing several probes for the *MEG3* locus, the deletion could be identified. To avoid false negative-molecular results in the diagnosis of patients with a clinical diagnosis of upd(14)mat or upd(14)pat syndrome it is necessary to improve and adopt the diagnostic strategies and methods to the current knowledge of molecular defects leading to the disease.

In summary, we could confirm the hypothesis of a hierarchical interaction and distinct functional properties of the IG-DMR and the *MEG3*-DMR in imprinting control of the 14q32 region.¹⁹ With the deep molecular analysis in patients with a maternal deletion of only

the *MEG3*-DMR the functional predominance of the IG-DMR could be proven. The family with patients 2 and 3 demonstrated the need for a detailed characterization of molecular alterations in 14q32 for accurate genetic counseling.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank the families for their cooperation. Furthermore we wish to thank Melanie Heitmann and Christina Lich for expert technical assistance and Bernhard Horsthemke for helpful discussion and critical reading of the manuscript. Part of this study was supported by the Bundesministerium für Bildung und Forschung (Network Imprinting diseases, 01GM1114). ME, MB, GGK and TE are members of the European Network of Congenital Imprinting Disorders (EUCID.net), supported by COST (BM1208).

- Wylie AA, Murphy SK, Orton TC, Jirtle RL: Novel imprinted *DLK1*/*GTL2* domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation. *Genome Res* 2000; **10**: 1711–1718.
- Charlier C, Segers K, Wagenaar D *et al*: Human-ovine comparative sequencing of a 250-kb imprinted domain encompassing the callipyge (*clpg*) locus and identification of six imprinted transcripts: *DLK1*, *DAT*, *GTL2*, *PEG11*, *antiPEG11*, and *MEG8*. *Genome Res* 2001; **11**: 850–862.
- Cavaille J, Seitz H, Paulsen M, Ferguson-Smith AC, Bachelier JP: Identification of tandemly-repeated C/D snoRNA genes at the imprinted human 14q32 domain reminiscent of those at the Prader-Willi/Angelman syndrome region. *Hum Mol Genet* 2002; **11**: 1527–1538.
- Seitz H, Royo H, Bortolin ML, Lin SP, Ferguson-Smith AC, Cavaille J: A large imprinted microRNA gene cluster at the mouse *Dlk1*-*Gtl2* domain. *Genome Res* 2004; **14**: 1741–1748.
- Paulsen M, Takada S, Youngson NA *et al*: Comparative sequence analysis of the imprinted *DLK1*-*Gtl2* locus in three mammalian species reveals highly conserved genomic elements and refines comparison with the *Igf2*-*H19* region. *Genome Res* 2001; **11**: 2085–2094.
- Lin SP, Youngson N, Takada S *et al*: Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the *Dlk1*-*Gtl2* imprinted cluster on mouse chromosome 12. *Nat Genet* 2003; **35**: 97–102.
- Kagami M, Sekita Y, Nishimura G *et al*: Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes. *Nat Genet* 2008; **40**: 237–242.
- Ogata T, Kagami M, Ferguson-Smith AC: Molecular mechanisms regulating phenotypic outcome in paternal and maternal uniparental disomy for chromosome 14. *Epigenetics* 2008; **3**: 181–187.
- Cotter PD, Kaffe S, McCurdy LD, Jhaveri M, Willner JP, Hirschhorn K: Paternal uniparental disomy for chromosome 14: a case report and review. *Am J Med Genet* 1997; **70**: 74–79.
- Kagami M, Nishimura G, Okuyama T *et al*: Segmental and full paternal isodisomy for chromosome 14 in three patients: narrowing the critical region and implication for the clinical features. *Am J Med Genet A* 2005; **138A**: 127–132.
- Temple IK, Cockwell A, Hassold T, Pettay D, Jacobs P: Maternal uniparental disomy for chromosome 14. *J Med Genet* 1991; **28**: 511–514.
- Pentao L, Lewis RA, Ledbetter DH, Patel PI, Lupski JR: Maternal uniparental isodisomy of chromosome 14: association with autosomal recessive rod monochromacy. *Am J Hum Genet* 1992; **50**: 690–699.
- Antonarakis SE, Blouin JL, Maher J, Avramopoulos D, Thomas G, Talbot CC Jr: Maternal uniparental disomy for human chromosome 14, due to loss of a chromosome 14 from somatic cells with t(13;14) trisomy 14. *Am J Hum Genet* 1993; **52**: 1145–1152.
- Mitter D, Buiting K, von Eggeling F *et al*: Is there a higher incidence of maternal uniparental disomy 14 [upd(14)mat]? Detection of 10 new patients by methylation-specific PCR. *Am J Med Genet A* 2006; **140**: 2039–2049.
- Temple IK, Shrubbs V, Lever M, Bullman H, Mackay DJ: Isolated imprinting mutation of the *DLK1*/*GTL2* locus associated with a clinical presentation of maternal uniparental disomy of chromosome 14. *J Med Genet* 2007; **44**: 637–640.
- Buiting K, Kanber D, Martin-Subero JI *et al*: Clinical features of maternal uniparental disomy 14 in patients with an epimutation and a deletion of the imprinted *DLK1*/*GTL2* gene cluster. *Hum Mutat* 2008; **29**: 1141–1146.
- Hosoki K, Ogata T, Kagami M, Tanaka T, Saitoh S: Epimutation (hypomethylation) affecting the chromosome 14q32.2 imprinted region in a girl with upd(14)mat-like phenotype. *Eur J Hum Genet* 2008; **16**: 1019–1023.
- Zechner U, Kohlschmidt N, Rittner G *et al*: Epimutation at human chromosome 14q32.2 in a boy with a upd(14)mat-like clinical phenotype. *Clin Genet* 2009; **75**: 251–258.

- 19 Kagami M, O'Sullivan MJ, Green AJ *et al*: The IG-DMR and the MEG3-DMR at human chromosome 14q32.2: hierarchical interaction and distinct functional properties as imprinting control centers. *PLoS Genet* 2010; **6**: e1000992.
- 20 Dietz LG, Wylie AA, Rauens KA, Murphy SK, Jirtle RL, Cotter PD: Exclusion of maternal uniparental disomy of chromosome 14 in patients referred for Prader-Willi syndrome using a multiplex methylation polymerase chain reaction assay. *J Med Genet* 2003; **40**: e46.
- 21 Begemann M, Leisten I, Soellner L, Zerres K, Eggermann T, Spengler S: Use of multilocus methylation-specific single nucleotide primer extension (MS-SNuPE) technology in diagnostic testing for human imprinted loci. *Epigenetics* 2012; **7**: 473–481.
- 22 Beygo J, Citro V, Sparago A *et al*: The molecular function and clinical phenotype of partial deletions of the IGF2/H19 imprinting control region depends on the spatial arrangement of the remaining CTCF-binding sites. *Hum Mol Genet* 2013; **22**: 544–557.
- 23 Steshina E, Carr M, Glick E, Yevtodiyenko A, Appelbe O, Schmidt J: Loss of imprinting at the *DLK1-Gtl2* locus caused by insertional mutagenesis in the *Gtl2* 5' region. *BMC Genetics* 2006; **7**: 44.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)